CurrentUnitedHealthcarePolicy CSO29TN.S

Cytological Examination of Breast Ductal Fluids (Ductal Lavage, Nipple Aspirate Fluid, Fiberoptic Ductoscopy)

This Tennessee-specific UnitedHealthcare medical policy governs use of cytological examination of breast ductal fluids (ductal lavage, nipple aspirate fluid, and fiberoptic ductoscopy) for breast cancer screening, diagnosis, and as alternative tools to guide surgery for Medicaid and CoverKids in Tennessee. It describes coverage rationale, evidence review, applicable CPT codes, and related guidance.

Policy Summary

PayerUnitedHealthcare

PolicyCytological Examination of Breast Ductal Fluids (Ductal Lavage, Nipple Aspirate Fluid, Fiberoptic Ductoscopy)

Policy CodePolicy CSO29TN.S

Change TypeSupporting Information Updated

Effective DateSep 1, 2025

Next Review Date

Key ActionWhen deciding coverage, reference federal, state, or contractual requirements as they may differ from this standard policy; federal/state/contractual requirements govern in event of conflict.

POLICY UPDATE CHANGES

Supporting Information Updated: Description of Services, Clinical Evidence, FDA, and References sections updated to reflect current information.

4Procedures Deemed Unproven/Not Medically Necessary

1CPT Codes Listed (reference)

Coverage Summary

Overview: This Tennessee-specific policy (Policy Number: CSO29TN.S, Effective 2025-09-01) governs cytologic examination of breast ductal fluids obtained by ductal lavage, nipple aspirate fluid (NAF), and fiberoptic ductoscopy (FDS) for Medicaid and CoverKids. The policy stance: these procedures are considered unproven and not medically necessary / not covered for breast cancer screening, diagnosis, or as alternative tools to guide surgery.

Key Policy Facts

Policy NumberCSO29TN.S

Effective DateSeptember 1, 2025

StatusCURRENT

ScopeThis Tennessee-specific UnitedHealthcare medical policy governs use of cytological examination of breast ductal fluids (ductal lavage, nipple aspirate fluid, and fiberoptic ductoscopy) for breast cancer screening, diagnosis, and as alternative tools to guide surgery for Medicaid and CoverKids in Tennessee.

Procedures Deemed Unproven/Not Medically Necessary4

CPT Codes Listed (reference)19499 (Unlisted procedure, breast)

Medical Necessity / Coverage Rationale

Coverage Rationale / Medical Necessity

The following are unproven and not medically necessary for use in breast cancer screening; breast cancer diagnosis; or screening as alternative tools to guide surgery due to insufficient evidence of efficacy:

ALL of the following

Breast ductal fluid aspiration and cytology (including ductal lavage and nipple aspirate fluid) is unproven and not medically necessary for breast cancer screening, diagnosis, or as an alternative tool to guide surgery due to insufficient evidence of efficacy.
Breast ductal lavage is unproven and not medically necessary for breast cancer screening, diagnosis, or as an alternative tool to guide surgery due to low sensitivity, high percentage of inconclusive results, and no evidence of mortality benefit when added to standard screening.
Nipple aspirate fluid (NAF) cytology is unproven and not medically necessary for breast cancer screening, diagnosis, or as an alternative tool to guide surgery due to poor sensitivity, sample inadequacy rates, and lack of evidence of improved clinical outcomes.
Fiberoptic ductoscopy (FDS), with or without ductal lavage, is unproven and not medically necessary for breast cancer screening, diagnosis, or as an alternative tool to guide surgery due to limited high-quality evidence demonstrating improved detection, outcomes, or mortality benefit.

Evidence summary and limitations: Overall evidence is limited and does not demonstrate clinical benefit. Key evidence points include: low sensitivity and high inadequate or inconclusive sample rates for ductal lavage and NAF cytology, variable specificity, and no demonstrated mortality benefit when added to standard screening; systematic reviews/meta-analyses and clinical practice guidelines do not support routine use. Specific evidence labels: NAF sensitivity (meta-analysis Jiwa et al. 2021): 0.64 (95% CI 0.62–0.66); specificity 0.97 (95% CI 0.97–0.98); mean 38.9% samples inadequate; Ductoscopy pooled sensitivity (Waaijer et al. 2016): pooled sensitivity ~94% (95% CI 88–97) with low specificity (47%) depending on definition; Ductal lavage diagnostic performance (various studies): low sensitivity, high inconclusive rates, and no demonstrated mortality benefit or reliable prediction of future cancer.

Not Covered / Experimental Services

Coverage stance: not_covered_cosmetic. Rationale: Ductal lavage, NAF cytology, fiberoptic ductoscopy (with or without lavage), and breast ductal fluid aspiration are considered unproven and not medically necessary based on the criteria above (insufficient evidence of efficacy, low sensitivity, high rates of inconclusive or inadequate samples, variable specificity, and lack of demonstrated mortality or outcome benefit). Therefore, these procedures are not covered for screening, diagnosis, or as alternatives to guide surgery.

Provider Actions

Documentation Required

Refer to federal/state/contractual benefit requirements

When deciding coverage, reference federal, state, or contractual requirements as they may differ from this standard policy; federal/state/contractual requirements govern in event of conflict.

Documentation Required

Use policy for interpretation only

This Medical Policy is informational to aid interpretation of UnitedHealthcare standard benefit plans and does not constitute medical advice; providers should document clinical rationale and reference applicable benefit plan terms.

Background and Evidence

Background: Cytologic examination of epithelial cells from breast ductal fluids (via ductal lavage, nipple aspiration/NAF, or fiberoptic ductoscopy) has been studied as a potential early indicator of breast cancer. Clinical studies and systematic reviews show low sensitivity for cancer detection, high percentages of inadequate or inconclusive samples, and variable specificity. There is insufficient evidence that these techniques improve cancer detection outcomes or reduce mortality, and guidelines do not recommend routine use.

Evidence Item	Finding
NAF sensitivity (meta-analysis Jiwa et al. 2021)	Sensitivity 0.64 (95% CI 0.62-0.66); specificity 0.97 (95% CI 0.97-0.98); mean 38.9% samples inadequate
Ductoscopy pooled sensitivity (Waaijer et al. 2016)	Pooled sensitivity ~94% (95% CI 88-97) with low specificity (~47%) depending on definition
Ductal lavage diagnostic performance (various studies)	Low sensitivity, high inconclusive/inadequate sample rates; no evidence of mortality benefit or reliable prediction of future cancer
Overall coverage stance / guideline conclusion	Breast ductal fluid aspiration/cytology, ductal lavage, nipple aspirate fluid cytology, and fiberoptic ductoscopy are unproven and not medically necessary for screening, diagnosis, or as alternatives to guide surgery due to insufficient evidence of efficacy

Definitions:

Ductal Lavage (DL): Invasive procedure inserting a microcatheter into breast ducts via the nipple to remove ductal fluid for cytologic analysis.

Nipple Aspirate Fluid (NAF): Fluid obtained from the nipple by noninvasive or minimally invasive methods (e.g., nipple aspiration) for cytologic or biomarker analysis.

Fiberoptic Ductoscopy (FDS): Endoscopic visualization of intraductal breast ducts using a very thin endoscope; may be performed with or without lavage.